Survival after Liver Transplantation of Patients with Primary Biliary Cirrhosis in the Nordic Countries Comparison with Expected Survival in Another Series of Transplantations and in an International Trial of Medical Treatment

1990 ◽  
Vol 25 (1) ◽  
pp. 11-18 ◽  
Author(s):  
S. Keiding ◽  
B.-G. Ericzon ◽  
S. Eriksson ◽  
A. Flatmark ◽  
K. Höckerstedt ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Medical Treatment ◽  
Nordic Countries ◽  
Biliary Cirrhosis ◽  
International Trial

Liver Transplantation for Primary Biliary Cirrhosis: Results of Aggressive Corticosteroid Withdrawal

2009 ◽  
Vol 41 (5) ◽  
pp. 1707-1712 ◽  
Author(s):  
J. Campsen ◽  
M. Zimmerman ◽  
J. Trotter ◽  
M. Wachs ◽  
T. Bak ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Biliary Cirrhosis ◽  
Corticosteroid Withdrawal

scholarly journals A case of acute hepatitis B on the patient of primary biliary cirrhosis who was registered for the brain-death donor liver transplantation

Kanzo ◽  
2014 ◽  
Vol 55 (3) ◽  
pp. 176-181 ◽  
Author(s):  
Mai Hirae ◽  
Takehisa Watanabe ◽  
Yoko Yoshimaru ◽  
Takeshi Kawasaki ◽  
Kazuhiro Izumi ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Hepatitis B ◽  
Brain Death ◽  
Acute Hepatitis ◽  
Biliary Cirrhosis ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Acute Hepatitis B ◽  
The Brain

scholarly journals Switching From Tacrolimus to Cyclosporine A to Prevent Primary Biliary Cirrhosis Recurrence After Living-Donor Liver Transplantation

10.9738/cc188 ◽  
2013 ◽  
Vol 98 (2) ◽  
pp. 156-159 ◽  
Author(s):  
Hiroaki Shiba ◽  
Shigeki Wakiyama ◽  
Yasuro Futagawa ◽  
Takeshi Gocho ◽  
Ryusuke Ito ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Cyclosporine A ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Immunosuppressive Agents ◽  
Biliary Cirrhosis ◽  
Protective Effects ◽  
Donor Liver ◽  
Donor Liver Transplantation

Abstract Recurrence of primary biliary cirrhosis (PBC) after liver transplantation has been shown to negatively affect graft and patient survival. Recently, protective effects of cyclosporine A against PBC recurrence after liver transplantation have been reported. Participants were 4 patients who underwent living-donor liver transplantation (LDLT) for end-stage liver disease due to PBC. Tacrolimus was used for initial immunosuppression, and this was switched to cyclosporine A at least 3 months after liver transplantation. Targeted trough level of cyclosporine A was 20 times that of tacrolimus. We assessed liver and renal function, as well as antimitochondrial M2 antibody for recipients prior to LDLT, as well as before and after switching immunosuppressive agents. Patients were 1 man and 3 women, and they were ages 45 to 47 years at LDLT. Timing of switching from tacrolimus to cyclosporine A was 13, 3, 7, and 4 months respectively after liver transplantation, and all 4 patients have been on cyclosporine A without adverse effects at 20 to 46 months after transplantation. In 2 of 4 patients who had high titers of antimitochondrial M2 antibody before transplantation, antibody titer did not elevate after LDLT. In the other 2 patients without elevation of antimitochondrial M2 antibody, the titer did not turn positive. Switching from tacrolimus to cyclosporine A was possible without medical problems, and all patients exhibit no recurrence of PBC. Cyclosporine A may be useful for prevention of PBC recurrence after LDLT.

Sign in / Sign up

Export Citation Format

Share Document